| HOME >> MEDICINE >> TECHNOLOGY |
State Intellectual Property Office (SIPO) 93
China provides 6 years of data exclusivity for pharmaceuticals, but it is not applied adequately in practice 94
Patent breakage 95
Case of Pfizer's Viagra fight in China 95
China's compulsory licensing policy is a cause for concern 96
Despite improvements China remains on the USTR Priority Watch List 96
Drug counterfeiting in China 97
China - Pricing and reimbursement 99
Pricing issues - continuing price cuts make China's business environment uncertain 99
The process for setting drug prices in China 100
Price cuts and the elimination of hospital mark-ups will make drugs more affordable 101
New Methods and Regulations on Drug Prices 103
Reimbursement issues in China 106
National Reimbursement Drug List (NRDL) 107
Essential Drug List (EDL) 108
Preferential purchasing of domestic drugs will hamper growth of foreign brands 109
Hospitals purchase drugs through a tendering system 109
Government crack down on overprescribing 110
Government initiatives to reduce reliance on hospital drug distribution have meant retail pharmacies are growing in importance 110
4. China - Pharmaceutical sales analysis 112
China - Key findings 112
Pharmaceutical market size 112
Leading therapy areas 112
Leading prescription pharmaceutical brands 112
Leading pharmaceutical companies 113
China - Pharmaceutical market size 114
China - Leading therapy areas 116
Infectious diseases drugs hold the largest share of the Chinese market value 118
Traditional Chinese medicines (TCMs) exhibited the strongest sales during 2005-09 119
China - Leading pharmaceutical brands 120
Shu Xue Ning achieved by far the highest sales in China in 2009 123
Ke Lin Ao 123
Plavix - FDA 'black box' warning may influence its sales in China
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |